Lannett Co. soon plans to begin shipping diethylproprion HCl tablets, used in the treatment of obesity.


Lannett, diethylproprion HCl tablets, Tenuate generic, obesity, Tenuate, Watson Pharmaceuticals, treatment of obesity, anti-obesity treatments, Arthur Bedrosian














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Lannett to release Tenuate generic

July 18th, 2011

PHILADELPHIA – Lannett Co. soon plans to begin shipping diethylproprion HCl tablets, used in the treatment of obesity.

The pharmaceutical company said Monday that it has received approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for diethylproprion HCl Tablets 25 mg.

The product is therapeutically equivalent to the reference listed drug, Watson Pharmaceuticals' Tenuate Tablets (25 mg), according to Lannett.

Diethylpropion is indicated as a short-term supplement to a regimen of diet and exercise in the treatment of obesity.

"Recognizing the struggle that many have with losing weight, we are pleased to offer diethylproprion HCl Tablets 25 mg, which further rounds out our portfolio of anti-obesity treatments," stated Arthur Bedrosian, president and chief executive officer of Lannett.  

Retail pharmacy sales of diethylproprion HCl Tablets 25 mg at average wholesale price totaled about $3.3 million for the year ended in May, according to Wolters Kluwer data cited by Lannett. 

Advertisement